◎记者 周亮 从广州生物岛的实验室到深圳坪山的产业园区，从中山的创新药企到珠海的医疗器械基地，生物医药科 技创新热潮正在南粤大地涌动。 近期，上海证券报记者在广东多地调研了解到，随着相关政策落地实施，广东创新药领域成果日益丰 硕。众多创新药企业在科研创新方面屡获突破，推动创新药走向市场化、产业化发展新阶段。 创新成果丰硕：从实验室迈向市场 中医药广东省实验室发布的中医横琴垂类大模型。 记者 周亮 摄 创新药密集获批上市，是政策驱动与产业集聚"双轮"发力的结果。广东省工业和信息化厅副厅长陈磊 称，广东生物医药产业的爆发式增长，依托于坚实的产业根基和独特的竞争优势。 数据显示，广东生物医药产业规模位居全国前列，近年来广东生物医药规上工业企业的营业收入年均复 合增长率超10%，医疗器械产业规模多年稳居全国第一。 据了解，广东拥有广州生物岛、深圳市生物医药创新产业园区、珠海国际健康港、中山健康科技产业基 地等专业的园区。广东生物医药平台载体发展潜力较强，还有新产业园在建设中。 近日，记者来到广州麓鹏制药有限公司临床前研发中心看到，该公司研发团队正围绕药物合成、杂质分 析、制剂工艺等核心环节进行严密测试与优化。 麓鹏制 ...

Policy Developments - The National Medical Products Administration (NMPA) held a meeting on May 28 to discuss the "Clearing Source" action in the drug distribution sector, emphasizing strict enforcement of regulations and collaboration across departments to ensure drug quality and safety [2]. Drug and Device Approvals - Novartis announced on May 28 that its anti-VEGF monoclonal antibody, Brolucizumab, has been approved by the NMPA for the treatment of diabetic macular edema (DME), allowing for injections every three months after the loading phase [4]. - On the same day, the NMPA accepted the new drug application (NDA) for Rocbrutinib, a fourth-generation BTK inhibitor developed by LuPeng Pharmaceutical, which is intended for adult patients with mantle cell lymphoma (MCL) who have previously received BTK inhibitor treatment [5]. Capital Market Activities - Zhenmai Bio completed a C+ round financing of 280 million yuan on May 28, with participation from multiple investors, aiming to focus on "commercial ecosystem construction" and "global expansion" [7]. Industry Events - On May 27, Anmai Bio announced a global licensing agreement with Juri Biosciences for the development of KLK2 and CD3 T-cell engaging molecules for metastatic prostate cancer, with potential payments up to 210 million USD [9]. - Eli Lilly announced on May 27 that it will acquire SiteOne Therapeutics, a startup focused on developing sodium channel inhibitors for pain management, with a total deal value of up to 1 billion USD [10]. Regulatory and Compliance Issues - ST Longjin announced on May 28 that it received a decision from the Shenzhen Stock Exchange to terminate its stock listing, effective June 27, 2025, due to non-compliance with listing rules [12]. - ST Jiyuan's stock will be delisted on May 29, 2025, after failing to maintain a closing price above 1 yuan for 20 consecutive trading days [14]. - ST Suwu reported on May 28 that it is under investigation by the China Securities Regulatory Commission (CSRC) for information disclosure violations, but its daily operations remain normal [15]. - Jiaying Pharmaceutical announced on May 28 that it is under investigation by the CSRC for suspected information disclosure violations and will cooperate with the regulatory body [16].